Shanghai Hengrui Pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd., explained in plain language.
Chinese pharmaceutical subsidiary of Hengrui, developing innovative drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New asthma drug shows promise in reducing severe attacks
Disease control OngoingThis study tests a new medicine called SHR-1905 for people with severe asthma that is not well controlled by current treatments. About 260 adults will receive either the drug or a placebo to see if it reduces asthma attacks and improves breathing and quality of life. The goal is …
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo HRS8807 and SHR6390 targets tough breast cancer
Disease control OngoingThis early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC